Latest Europe News

Redivium Limited has postponed the completion of its UK lithium-ion battery recycling feasibility study to Q2 2026 due to a site relocation requiring updated environmental assessments. Meanwhile, its European projects in Czechia and Romania continue to advance steadily.

Redivium Limited is advancing a recapitalisation strategy with Australian investors to meet ASX requirements and resume trading after a prolonged suspension.

Element 25 Limited has announced significant progress in expanding its Butcherbird manganese mine and developing a US-based high-purity manganese refinery, backed by substantial government grants and strategic partnerships with automotive giants.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.

Sarytogan Graphite Limited has raised $1.8 million through a placement to fund its Definitive Feasibility Study and advance key project development activities at its strategic graphite deposit in Kazakhstan.

Harvey Norman Holdings reports a robust 9.1% increase in aggregated sales revenue across key international markets, supported by currency appreciation and selective store openings.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Straker Ltd reports a solid first half of FY26 with positive EBITDA and a renewed IBM partnership, despite a 15% revenue decline amid challenging market conditions.

PC Gold has secured a dual listing on the Frankfurt Stock Exchange, opening new doors to European investors as it advances its Spring Hill Gold Project in Australia’s Northern Territory.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

Global Masters Fund Limited (GFL) reported a robust 19.8% total return for FY2025, surpassing the MSCI World Index, while unveiling strategic moves to diversify beyond Berkshire Hathaway into private growth and regional quality funds.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.